The unveiling of the Asco abstracts is one of the biggest events of the year for followers of oncology stocks and, despite going virtual for the second year running, 2021 looks set to deliver its fair share of crucial updates.
Much of the most important data remains under wraps, however, with late breaking abstracts due to be release at 5pm ET on June 3, the day before the meeting gets under way. Small cap developers have delivered the sharpest share price rises so far, with Sensei and PDS jumping 30% and 27% on largely incremental updates. Meanwhile Merus’s bispecific update failed to excite, with the stock ending up down 16%.
First to the risers, with newly-listed immuno-oncology player Sensei getting a boost from data from an ongoing trial of its lead asset in head and neck cancer. SNS-310 is an inactivated bacteriophage virus expressing ASPH, an antigen that Sensei says is over-expressed in several tumour types.
A poster presentation will detail responses in 12 patients who failed to respond to PD-1 blockade, with a 67% (8/12) response rate, including one partial response and seven cases of stable disease.
Despite the share price jump to $12.66 Sensei stock remains well below the $19 at which it floated in January. PDS stock, meanwhile, is now trading at its highest level since the company reversed into a failed biotech back in March 2019, thanks to data being generated by an NCI-led study of the company’s lead project, PDS0101.
A triple combination of PDS0101 and two Merck KGaA assets – the IL-12 asset M9241 and TGF-β/PD-L1 fusion protein bintrafusp alfa – is being trialled in patients with refractory HPV16-associated cancers. The abstract details a 71% (10/14) ORR, with one complete response and nine partials, although a later cut of the data is expected at the conference.
|Important Asco late breaking and plenary abstracts|
Merck & Co
|Lynparza||Olympia: ph3 trial of adjuvant Lynparza after (neo)adjuvant chemo in germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer||LBA1|
|Merck & Co||Keytruda||Keynote-564: ph3 trial of Keytruda as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma||LBA5|
|Novartis||177Lu-PSMA-617||Vision: Ph3 trial of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer||LBA4|
|Tuoyi||Jupiter-02: ph3 trial of Tuoyi (toripalimab) plus chemo as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma||LBA2|
|Bristol Myers Squibb||Opdivo & Yervoy||Checkmate-648: Opdivo plus Yervoy or chemo as first-line treatment for advanced oesophageal squamous cell carcinoma First results of the CheckMate 648 study.||LBA4001|
Other risers yesterday included Lag3 developer Immutep, which is presenting three posters at the conference containing updates from ongoing trials of eftilagimod alpha. The stock jump yesterday, taking the Australian developer to a six-year high, was more to do with Bristol Myers Squibb’s success with its Lag3 asset, relatlimab.
Merus was not the only faller yesterday, with Alpine Immune and Black Diamond Therapeutics also nursing losses, down 17% and 37% respectively.
One unconfirmed partial response among 11 evaluable subjects from Alpine’s CD28 costimulator and dual checkpoint inhibitor, ALPN-202, failed to impress. Dose escalation continues, however.
Black Diamond meanwhile is targeting intractable tumour types driven by various EGFR or HER2 mutations. At the maximum tolerated dose for once-a-day pill BDTX-189 generated two partial responses, only one of which was confirmed, three cases of stable disease and progressive disease in 10 subjects.
Enrolment in other dosing cohorts is ongoing but these data were a big disappointment from another of 2021’s IPO cohort. The stock is now trading 17% below its float price, with yesterday’s plunge erasing $300m from the company’s market cap.
This is far from an exhaustive review of notable presentations, of course, and with much more data due in the coming weeks, the Asco trading period is far from over.
|Selected Asco abstracts of note|
|Adaptimmune||Afami-cel||Anti-Mage-A4 eTCR||11504||Adaptimmune’s T-cell receptors see a route to market|
|Alkermes||Nemvaleukin||IL-2 mimic||2513||Responses seen in monotherapy and with Keytruda across various tumours|
|Allogene||ALLO-501||Anti-CD19 allo Car-T||2529||Off-the-shelf cell therapy inches towards reality|
|Alpine Immune||ALPN-202||Conditional CD28 costimulator and dual checkpoint inhibitor||2547||Ph1 dose escalation; 1 unconfirmed PR and 5 SD in 11 subjects|
|Arcus||Etrumadenant + zimberelimab + AB680||A2aR/A2bR antagonist + anti-PD-1 + anti-CD73||5039||In evaluable pts, PSA response 5/14, radiographic response 3/8, with 1 CR, composite response rate was 43% (6/14)|
|Black Diamond||BDTX-189||EGFR/HER2 kinase inhibitor||3086||Of 15 evaluable, 1 confirmed PR, 3 SD and 10 progressive disease|
|Bristol Myers Squibb||Relatlimab||Anti-Lag3 MAb||9503||Bristol’s Lag3 case for a replacement for Yervoy|
|Cullinan||CLN-081||EGFR Exon20 inhibitor||9077||Of 25 evaluable, 10 PRs, 14 SD, 1 progressive disease. Later cut to be presented|
|G1||Rintodestrant||SERD||1063||Ph1 safety data: rintodestrant-related AEs in 8%, all grade 2|
|I-Mab||Uliledlimab||Anti-CD73 MAb||2511||Of 13 evaluable, 3 CRs or PRs (ORR 23%) and 3 SD (disease control rate 46%).|
|Immunogen||Mirvetuximab||Anti-FRα ADC||5504||Of 33 pts with high FRα expression ORR 64%, mDOR of 11.8 months, and mPFS of 10.6 months (Forward I study failed in all-comers)|
|Immutep||eftilagimod alpha||Lag3||9046; 6028; 2518||Data from ongoing Ph2 trials in combination with Keytruda (NSCLC & H&N), and Ph1 plus Bavencio.|
|Kadmon||KD033||Anti-PD-L1/IL-15 fusion protein||2568||Of 6 evaluable, 1 SD|
|Macrogenics||MGC018||Anti-B7-H3 ADC||2631||3 unconfirmed PRs in melanoma pts|
|Merus||Zenocutuzumab||Anti-Her2/Her3 bispecific||3003||Merus intrigues in pancreatic cancer|
|Roche||Tecentriq||Anti-PD-L1 MAb||8500||Adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers|
T-cell surface glycoprotein CD8 stimulant
|2536||4 SD in 10 evaluable pts|
|Sutro||STRO-002||FRα inhibitor||5550||Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR. Disease control rate was 74% at 12 weeks and 61% at 16 weeks.|
|Sensei||SNS-301||ASPH targeted bacteriophage||6029||67% response rate in 12 PD-1 refractory H&N patients|
|PDS Biotech||PDS0101||HPV targeted T cell activator||2501||In combination with M9241 and bintrafusp alfa, ORR of 71%|
|Source: Asco abstracts.|